



Grant Thornton

Glenmark Pharmaceuticals s.r.o.

REPORT

**ON THE AUDIT
OF FINANCIAL STATEMENTS
AS AT 31 MARCH 2024**



CONTENTS

- **Independent Auditor's Report**
- **Balance Sheet as at 31.03.2024**
- **Income Statement for the period 01.04.2023 - 31.03.2024**
- **Statement of Changes in Equity for the 01.04.2023 - 31.03.2024**
- **Cash Flow Statement for the 01.04.2023 - 31.03.2024**
- **Notes to the Financial Statements**
- **Annual Report**
- **Report on relationships between a controlling and a controlled entity**

The electronic version of this document can be deemed as reliable and legally binding only if accompanied by a qualified auditor's certificate. This is a translation of the original Czech Auditor's Report on the accompanying financial statements. Therefore, in the event of any inconsistency between the English and the Czech version, the Czech version shall prevail. For a full understanding of the information stated in the Auditor's Report, the Report should be read in conjunction with the full set of financial statements prepared in Czech.

INDEPENDENT AUDITOR'S REPORT

To the Shareholder

Glenmark Pharmaceuticals s.r.o.

Registered Address: Praha 4, Hvězdova 1716/2b, PSČ 14078

Company Identification Number (IČ): 465 05 164

Auditor's Opinion

We have audited the accompanying financial statements of Glenmark Pharmaceuticals s.r.o. (hereinafter also the "Company") prepared in accordance with accounting principles generally accepted in the Czech Republic, showing a balance sheet total of 3.187.379 thds. CZK and a profit of 147.543 thds. CZK. These financial statements comprise the balance sheet as at 31 March 2024, and the income statement, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including significant (material) information on accounting methods used.

In our opinion, the financial statements give a true and fair view of the financial position of the Company as at 31 March 2024 and of its financial performance and its cash flows for the year then ended in accordance with accounting principles generally accepted in the Czech Republic.

Basis for Opinion

We conducted our audit in accordance with the Act on Auditors, and Auditing Standards of the Chamber of Auditors of the Czech Republic, which are International Standards on Auditing (ISAs), as amended by the related application clauses. Our responsibilities under these laws and regulations are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the Act on Auditors and the Code of Ethics adopted by the Chamber of Auditors of the Czech Republic and we have fulfilled our ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information presented in the Annual Report

In compliance with Section 2(b) of the Act on Auditors, other information comprises the information included in the Annual Report other than the financial statements and auditor's report thereon. The Managing Directors are responsible for the other information.

Our opinion on the financial statements does not cover the other information. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated. In addition, we assess whether the other information has been prepared, in all material aspects, in accordance with applicable law or regulation, in particular, whether the other information complies with law or regulation in terms of formal requirements and

The electronic version of this document can be deemed as reliable and legally binding only if accompanied by a qualified auditor's certificate. This is a translation of the original Czech Auditor's Report on the accompanying financial statements. Therefore, in the event of any inconsistency between the English and the Czech version, the Czech version shall prevail. For a full understanding of the information stated in the Auditor's Report, the Report should be read in conjunction with the full set of financial statements prepared in Czech.

procedure for preparing the other information in the context of materiality, i.e. whether any non-compliance with these requirements could influence judgements made on the basis of the other information.

Based on the procedures performed, to the extent we are able to assess it, we report that:

- The other information describing the facts that are also presented in the financial statements is, in all material aspects, consistent with the financial statements; and
- The other information is prepared in compliance with applicable law or regulation.

In addition, our responsibility is to report, based on the knowledge and understanding of the Company obtained in the audit, that the other information does not contain any material misstatement of fact. Based on the procedures we have performed on the other information obtained, we have not identified any material misstatement of fact.

Responsibilities of the Company's Managing Directors (hereinafter also "Company's statutory body") for the Financial Statements

Company's statutory body is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the Czech Republic and for such internal control as the statutory body determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Company's statutory body is responsible for assessing the Company's ability to continue as a going concern, disclosing in the notes to the financial statements, as applicable, matters related to going concern and using the going concern basis of accounting unless the Company's statutory body either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the above mentioned regulations will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with the above law or regulation, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

The electronic version of this document can be deemed as reliable and legally binding only if accompanied by a qualified auditor's certificate. This is a translation of the original Czech Auditor's Report on the accompanying financial statements. Therefore, in the event of any inconsistency between the English and the Czech version, the Czech version shall prevail. For a full understanding of the information stated in the Auditor's Report, the Report should be read in conjunction with the full set of financial statements prepared in Czech.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting methods used and the reasonableness of accounting estimates and related disclosures made by the Company's statutory body in the notes to the financial statements.
- Conclude on the appropriateness of the statutory body's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the Company's statutory body regarding, among other matters, the planned scope and timing of the audit and our significant audit findings, including any significant deficiencies identified in the internal controls.



Grant Thornton Audit s.r.o.

Pujmanové 1753/10a, 140 00 Praha 4 - Nusle

Licence No. 603

Ing. Michal Kováč
Auditor, Licence No. 1188

**Financial statements
for the year ended 31.3.2024**

Name of accountancy unit: Glenmark Pharmaceuticals s.r.o.
Seat: Hvězdova 1719/2b
Praha 4
14078
Identif. Code: 46505164

Compiled on: 21.5.2024

Components of the Financial Statements:

Balance Sheet
Profit and Loss Statement
Statement of changes in Equity
Cash Flow Statement
Notes to the Financial Statements
Report on relationships between a controlling and a controlled entity

Name of statutory body or individual, who is an accounting unit:	Signature
Petr Podlipný	
Person responsible for financial statements (Name)	Signature
Jana Neradová	

BALANCE SHEET

in full scale

as of 31.3.2024

(in entire thousands CZK)

Name and seat
of accountancy unit

Glenmark Pharmaceuticals s.r.o.

Identif. Code:

46505164

Hvězdova 1719/2b

Praha 4

14078

Denotation a	A S S E T S b	Current accounting period			Previous acc. period Netto 4
		Brutto 1	Correction 2	Netto 3	
	TOTAL ASSETS	3 960 310	- 772 931	3 187 379	2 636 910
A.	Amounts receivable for subscribed registered capital				
B.	Fixed assets	1 500 778	- 699 494	801 284	690 748
B. I.	Long-term intangible assets	1 044 203	- 497 610	546 593	450 983
B. I. 1.	Intangible results of development				
B. I. 2.	Valuable rights (patents, licences and know-how)	830 224	- 493 038	337 186	330 485
B. I. 2.1.	Software	2 572	- 2 110	462	660
B. I. 2.2.	Other valuable rights (patents, licences and know-how)	827 652	- 490 928	336 724	329 825
B. I. 3.	Goodwill				
B. I. 4.	Other long-term intangible assets				
B. I. 5.	Advances for intangible fixed assets and intangible fixed assets under construction	213 979	- 4 572	209 407	120 498
B. I. 5.1.	Advances for long-term intangible assets				
B. I. 5.2.	Intangible fixed assets under construction	213 979	- 4 572	209 407	120 498
B. II.	Long-term tangible assets	403 607	- 201 884	201 723	195 244
B. II. 1.	Land and structures	212 103	- 94 353	117 750	119 920
B. II. 1.1.	Land	983		983	983
B. II. 1.2.	Structures	211 120	- 94 353	116 767	118 937
B. II. 2.	Plant and equipment	185 125	- 107 531	77 594	63 575
B. II. 3.	Goodwill, incl. market value increment				
B. II. 4.	Other long-term tangible assets				
B. II. 4.1.	Forests, orchards etc.				
B. II. 4.2.	Full-grown animals and their herds				
B. II. 4.3.	Other long-term tangible assets				
B. II. 5.	Advances for tangible fixed assets and tangible fixed assets under construction	6 379		6 379	11 749
B. II. 5.1.	Advances for tangible fixed assets	123		123	7 086
B. II. 5.2.	Long-term tangible assets in progress	6 256		6 256	4 663
B. III.	Long-term financial assets	52 968		52 968	44 521
B. III. 1.	Equity investments - group undertakings	52 968		52 968	44 521
B. III. 2.	Loans - controlled and controlling organizations				
B. III. 3.	Equity investments - associated companies				
B. III. 4.	Loans - associated companies				
B. III. 5.	Other long-term securities and equity investments				
B. III. 6.	Loans - other				
B. III. 7.	Other long-term investments				
B. III. 7.1.	Other long-term investments				
B. III. 7.2.	Advances for long-term financial assets				

Denotation a	A S S E T S b	Current accounting period			Previous acc. period
		Brutto 1	Correction 2	Netto 3	Netto 4
C.	Current assets	2 218 393	- 73 437	2 144 956	1 663 054
C. I.	Inventories	493 060	- 73 437	419 623	326 622
C. I. 1.	Materials	65 222	- 881	64 341	51 278
C. I. 2.	Work-in-progress and semi-finished products	17 699		17 699	11 862
C. I. 3.	Finished goods and goods for resale	410 139	- 72 556	337 583	263 482
C. I. 3.1.	Finished goods	24 519	- 995	23 524	7 161
C. I. 3.2.	Purchased goods for resale (inc. goods in transit)	385 620	- 71 561	314 059	256 321
C. I. 4.	Young and other animals and their herds				
C. I. 5.	Advance payments for inventories				
C. II.	Receivables	1 414 645		1 414 645	1 189 278
C. II. 1.	Long-term receivables	106 065		106 065	73 085
C. II. 1.1.	Trade receivables				
C. II. 1.2.	Inter-group receivables (controlled or controlling entity)				
C. II. 1.3.	Inter-group receivables - significant influence				
C. II. 1.4.	Deferred tax receivable	103 892		103 892	70 916
C. II. 1.5.	Receivables - other	2 173		2 173	2 169
C. II. 1.5.1.	Receivables from partners				
C. II. 1.5.2.	Long-term advances granted	2 173		2 173	2 169
C. II. 1.5.3.	Estimated receivables				
C. II. 1.5.4.	Other receivables				
C. II. 2.	Short-term receivables	1 308 580		1 308 580	1 116 193
C. II. 2.1.	Trade receivables	1 100 267		1 100 267	1 072 875
C. II. 2.2.	Inter-group receivables (controlled or controlling entity)	62		62	
C. II. 2.3.	Inter-group receivables - significant influence				
C. II. 2.4.	Receivables - other	208 251		208 251	43 318
C. II. 2.4.1.	Receivables from partners				
C. II. 2.4.2.	Social security and health insurance				
C. II. 2.4.3.	Due from state - tax receivables	3 606		3 606	13 727
C. II. 2.4.4.	Short-term advances granted	3 064		3 064	1 902
C. II. 2.4.5.	Estimated receivables	201 521		201 521	27 680
C. II. 2.4.6.	Other receivables	60		60	9
C. III.	Short-term financial assets				
C. III. 1.	Equity investments - group undertakings				
C. III. 2.	Other short-term financial assets				
C. IV.	Cash	310 688		310 688	147 154
C. IV. 1.	Cash in hand				
C. IV. 2.	Bank accounts	310 688		310 688	147 154
D. I.	Accruals	241 139		241 139	283 108
D. I. 1.	Prepaid expenses	241 139		241 139	283 108
D. I. 2.	Complex prepaid expenses				
D. I. 3.	Accrued income				

Denotation a	E Q U I T Y + L I A B I L I T I E S b	Current acc. period 5	Previous acc. period 6
	TOTAL EQUITY + LIABILITIES	3 187 379	2 636 910
A.	Equity	1 336 304	1 180 314
A. I.	Registered capital	60 000	60 000
A. I. 1.	Registered capital	60 000	60 000
A. I. 2.	Own shares/ownership interests (-)		
A. I. 3.	Changes in registered capital		
A. II.	Premium and capital funds	2 489 286	2 480 839
A. II. 1.	Share premium	18 587	18 587
A. II. 2.	Capital funds	2 470 699	2 462 252
A. II. 2.1.	Other capital funds	2 448 318	2 448 318
A. II. 2.2.	Valuation differences from re-valuation of assets and liabilities (+/-)	22 381	13 934
A. II. 2.3.	Differences from revaluation in transformation of companies (+/-)		
A. II. 2.4.	Differences from transformation of companies (+/-)		
A. II. 2.5.	Differences from valuation in transformation of companies (+/-)		
A. III.	Funds from earnings	8 529	8 529
A. III. 1.	Other reserve funds	8 498	8 498
A. III. 2.	Statutory and other funds	31	31
A. IV.	Retained profit or loss from prior year (+/-)	- 1 369 054	- 1 401 110
A. IV. 1.	Retained earnings or losses (+/-)	- 1 369 054	- 1 401 110
A. IV. 2.	Other profit or loss from previous years (+/-)		
A. V.	Profit or loss of the current accounting period (+/-)	147 543	32 056
A. VI.	Approved advance profit distribution (-)		
B. + C.	Liabilities	1 850 769	1 456 124
B.	Provisions	247 766	191 064
B. I.	Provision for pensions and similar liabilities		
B. II.	Provision for income tax		
B. III.	Provisions made according to special legal regulations		
B. IV.	Other provisions	247 766	191 064

Denotation a	EQUITY + LIABILITIES b	Current acc. period 5	Previous acc. period 6
C.	Liabilities	1 603 003	1 265 060
C. I.	Long-term liabilities	30 966	62 312
C. I. 1.	Issued bonds		
C. I. 1.1.	Convertible debentures and bonds		
C. I. 1.2.	Other debentures and bonds		
C. I. 2.	Liabilities to credit institutions		
C. I. 3.	Long-term advances received		
C. I. 4.	Trade payables		
C. I. 5.	Long-term promissory notes		
C. I. 6.	Inter-group payables (controlled or controlling entity)		
C. I. 7.	Inter-group payables - significant influence		
C. I. 8.	Deferred tax payable		
C. I. 9.	Liabilities - other	30 966	62 312
C. I. 9.1.	Payables to partners		
C. I. 9.2.	Estimated payables		
C. I. 9.3.	Other payables	30 966	62 312
C. II.	Short-term liabilities	1 572 037	1 202 748
C. II. 1.	Issued bonds		
C. II. 1.1.	Convertible debentures and bonds		
C. II. 1.2.	Other debentures and bonds		
C. II. 2.	Liabilities to credit institutions		
C. II. 3.	Short-term advances received		
C. II. 4.	Trade payables	1 387 443	1 068 356
C. II. 5.	Short-term bills of exchange payable		
C. II. 6.	Inter-group payables (controlled or controlling entity)		
C. II. 7.	Inter-group payables - significant influence		
C. II. 8.	Liabilities - other	184 594	134 392
C. II. 8.1.	Payables to partners		
C. II. 8.2.	Other short-term borrowings		
C. II. 8.3.	Payables to employees	8 408	7 682
C. II. 8.4.	Social security and health insurance payables	4 510	4 077
C. II. 8.5.	Due to state - taxes and subsidies	48 030	14 007
C. II. 8.6.	Estimated payables	86 614	81 874
C. II. 8.7.	Other payables	37 032	26 752
D.	Accruals	306	472
D. I.	Accrued expenses	306	472
D. II.	Deferred income		

PROFIT AND LOSS STATEMENT - classification by types

in full scale
as of 31.3.2024
(in entire thousands CZK)

Name and seat
of accountancy unit

Glenmark Pharmaceuticals s.r.o.

Identif. Code:
46505164

Hvězdova 1719/2b
Praha 4
14078

Denotation a	T E X T b	Accounting period	
		Current 1	Previous 2
I.	Revenue from products and services	561 405	415 593
II.	Sales of goods bought for resale	3 528 275	3 031 673
*	Total sales	4 089 680	3 447 266
A.	Purchased consumables and services	3 630 791	3 217 207
A. 1.	Cost of goods sold	2 393 321	2 152 387
A. 2.	Consumables	392 838	254 684
A. 3.	Services	844 632	810 136
B.	Change in inventory of own production (+/-)	- 21 692	26 971
C.	Own work capitalized (-)		
D.	Staff costs	141 851	121 194
D. 1.	Wages and salaries	102 958	87 443
D. 2.	Social security, health insurance and other expenses	38 893	33 751
D. 2. 1.	Social security and health insurance expenses	31 995	27 637
D. 2. 2.	Other expenses	6 898	6 114
E.	Adjustments relating to operating activities	123 553	62 071
E. 1.	Adjustments to intangible and tangible fixed assets	71 714	56 481
E. 1. 1.	Depreciation and amortization of intangible and tangible fixed assets	67 486	65 033
E. 1. 2.	Impairment of intangible and tangible fixed assets	4 228	- 8 552
E. 2.	Adjustments to inventories	51 877	5 564
E. 3.	Adjustments to receivables	- 38	26
III.	Other operating revenues	344 302	374 177
III. 1.	Proceeds from disposals of fixed assets	13	17 321
III. 2.	Proceeds from disposals of raw materials	2 876	3 672
III. 3.	Other operating revenues	341 413	353 184
F.	Other operating expenses	402 384	342 677
F. 1.	Net book value of fixed assets sold	9	15 430
F. 2.	Material sold		35
F. 3.	Taxes and charges	474	328
F. 4.	Provisions relating to operating activity and complex prepaid expenses	56 702	54 840
F. 5.	Other operating expenses	345 199	272 044
*	Operating profit or loss (+/-)	157 095	51 323

Denotation a	T E X T b	Accounting period	
		Current 1	Previous 2
IV.	Revenue from long-term investments - equity investments		
IV. 1.	Revenue from equity investments - group undertakings		
IV. 2.	Other revenue from equity investments		
G.	Cost of equity investments sold		
V.	Revenue from other long-term investments		
V. 1.	Revenue from other long-term investments - group undertakings		
V. 2.	Other revenue from other long-term investments		
H.	Expenses related to other long-term investments		
VI.	Interest revenue and similar revenue	220	169
VI. 1.	Interest revenue and similar revenue - group undertakings	62	
VI. 2.	Other interest revenue and similar revenue	158	169
I.	Adjustments and provisions relating to financial activity		
J.	Interest expense and similar expense	6 799	8 173
J. 1.	Interest expense and similar expense - group undertakings		
J. 2.	Other interest expense and similar expense	6 799	8 173
VII.	Other financial revenues	152 484	78 079
K.	Other financial expenses	129 098	79 230
*	Profit (loss) from financial operations	16 807	- 9 155
**	Profit (loss) before tax (+/-)	173 902	42 168
L.	Income tax	26 359	10 112
L. 1.	Current tax	59 336	18 254
L. 2.	Deferred tax (+/-)	- 32 977	- 8 142
**	Profit (loss) after tax (+/-)	147 543	32 056
M.	Transfer of profit or loss to shareholders/members (+/-)		
***	Profit (loss) for the accounting period (+/-)	147 543	32 056
*	Net turnover for the accounting period = I. + II. + III. + IV. + V. + VI. +	4 586 686	3 899 691

**STATEMENT OF
CHANGES IN EQUITY**

as of
(in entire thousands CZK)

Identif. Code:

Name and seat
of accountancy unit
Glenmark Pharmaceuticals s.r.o.
Hvězdova 1719/2b
Praha 4
14078

	Share capital	Own shares/ ownership interests (-)	Share premium	Other capital funds	Differences from revaluation	Differences from transformation	Funds from profit, reserve fund	Retained earnings or losses (+/-)	Other profit or loss from previous years	Profit or loss for the current period	TOTAL EQUITY
Balance at 31.3.2022	60 000		18 587	2 448 318	3 485		8 529	-1 487 889		86 779	1 137 809
Distribution of profit or loss								86 779		-86 779	
Change in share capital											
Profit shares paid											
Profit share prepayments declared											
Changes in capital funds					10 449						10 449
Profit or loss for the current period										32 056	32 056
Balance at 31.3.2023	60 000		18 587	2 448 318	13 934		8 529	-1 401 110		32 056	1 180 314
Distribution of profit or loss								32 056		-32 056	
Change in share capital											
Profit shares paid											
Profit share prepayments declared											
Changes in capital funds					8 447						8 447
Profit or loss for the current period										147 543	147 543
Balance at 31.3.2024	60 000		18 587	2 448 318	22 381		8 529	-1 369 054		147 543	1 336 304

CASH FLOW STATEMENT

as of **31.3.2024**
(in entire thousands CZK)

Name and seat
of accountancy unit
Glenmark Pharmaceuticals s.r.o.

Identif. Code:
46505164

Hvězdova 1719/2b
Praha 4
14078

Den. a	TEXT b	Balance in accounting period	
		current 1	previous 2
P.	Cash and cash equivalents, beginning of period	147 154	170 103
	Net operating cash flow	-	-
Z.	Accounting profit (loss) from ordinary activities	173 902	42 168
A. 1.	Non-cash transactions	186 830	123 024
1. 1.	Depreciation of fixed assets	67 486	65 033
2.	Change in:	112 769	51 878
2. 1.	goodwill and adjustments to acquired assets		
2.	provisions and other adjustments	112 769	51 878
3.	Profit(-) Loss(+) on sale of fixed assets	- 4	- 1 891
4.	Profit(-) Loss(+) on sale of securities		
5.	Revenue from dividends and profit distribution		
6.	Expense and revenue interests accounted for	6 579	8 004
7.	Other non-cash transactions		
A. *	Net operating cash flow before financial items, changes in working capital and extraordinary items	360 732	165 192
A. 2.	Changes in working capital	15 773	- 63 208
2. 1.	Change in receivables from operating activities and deferrals	- 150 422	- 81 002
2.	Change in short-term liabilities from operating activities and accruals	311 073	152 656
3.	Change in inventories	- 144 878	- 134 862
4.	Change in short-term financial assets, other than cash and cash equivalents		
A. **	Net operating cash flow before financial balances, tax and extraordinary items	376 505	101 984
A. 3.	Interest paid excluding amounts capitalised		
A. 4.	Interest received	158	169
A. 5.	Income tax paid on ordinary income and income tax relating to prior periods		
A. 6.	Dividends received		
A. ***	Net operating cash flow	376 663	102 153

Den. a	TEXT b	Balance in accounting period	
		current 1	previous 2
	Investment activity	-	-
B. 1.	Acquisition of fixed assets	- 213 142	- 126 993
1. 1.	Acquisition of tangible fixed assets	- 135 527	- 86 665
2.	Acquisition of intangible fixed assets	- 77 615	- 40 328
3.	Acquisition of long-term investments		
B. 2.	Proceeds from sales of fixed assets	13	1 891
2. 1.	Proceeds from sales of tangible and intangible fixed assets	13	1 891
2.	Proceeds from sale of financial investments		
B. 3.	Advances and loans to related parties		
B. ***	Net cash flow from investment activity	- 213 129	- 125 102
	Financial activity	-	-
C. 1.	Change in long-term liabilities and bank loans		
C. 2.	Increase and decrease in equity from cash transactions		
2. 1.	Subscription of shares and investments, even. Funds from earnings		
2.	Equity paid to shareholders		
3.	Other cash contributions from partners and shareholders		
4.	Loss settlement from partners		
5.	Payments from funds created from net profit		
6.	Dividends paid, including withholding tax paid		
C. ***	Net cash flow from financial activity		
F.	Net increase or decrease in cash balance	163 534	- 22 949
R.	Cash and cash equivalents, end of period	310 688	147 154

NOTES TO THE FINANCIAL STATEMENTS
as of March 31, 2024

Glenmark Pharmaceuticals s.r.o.

Registered address: Hvězdova 1716/2b, 140 78 Praha 4

Legal status: Limited Liability Company

ID: 46505164

1. GENERAL INFORMATION

1.1. Subject of activity

Glenmark Pharmaceuticals s.r.o. (hereinafter „Company“), Company Registration No.: **46505164**, is a limited liability company, registered in the Commercial Register on May 6, 1992 at the Citi Court in Prague, Section C, insert 150331. The address of the Company's seat is Hvězdova 1716/2b, 140 78 Prague 4.

The main business activities of the Company are as follows:

- Distribution of pharmaceuticals and medical equipment
- Chemical analyses
- Manufacturing of infusion solutions
- Manufacturing of pharmaceutical preparations

On March 31, 2016 there was a transfer of a part of the business establishment called CZ distribution business and CEEHQ to Glenmark Pharmaceuticals Distribution s.r.o., headquartered Hvězdova 1716 / 2b, Nusle, 140 78 Praha 4, VAT ID 04727339, registered in the Commercial Register maintained by the Municipal court in Prague, section C, File 252762.

1.2. Ownership structure

Name of owner	Address	Ownership interest %
Glenmark Holding SA	La Chaux-de-Fonds, Chemin de la Combeta 5, Switzerland confederation	100%
Total		100%

As of March 31, 2024, shares of 20% or more of the company's registered capital are held:

Name	Address	Ownership interest	Equity (in ths EUR)	Profit (in ths EUR)
GLENMARK PHARMACEUTICALS SK, s. r. o.	Tomášikova 64 83104 Bratislava	100%	2 093	198

Glenmark Pharmaceuticals s.r.o.

As of March 31, 2023, shares of 20% or more of the company's registered capital are held:

Name	Address	Ownership interest	Equity (in ths EUR)	Profit from previous period (in ths EUR)
GLENMARK PHARMACEUTICALS SK, s. r. o.	Tomášikova 64 83104 Bratislava	100%	1 895	498

Financial data is based on subsidiary's audited financial statements.

Glenmark Pharmaceuticals s.r.o is the part of Glenmark group, which has its consolidated financial statements prepared by the Glenmark Pharmaceuticals Ltd. (Glenmark House, B.D., Sawant Marg, Chakala, Off, Western Express Highway, Andherei (East), Mumbai – 400 099, India).

Financial result for the year ended March 31, 2023 was approved on August 29, 2023 and the profit of the company was transferred to the account retained earnings.

The Shareholder intends to transfer the profit of the year ended March 31, 2024 to the account retained earnings.

1.3. Statutory representatives as of March 31, 2024


Oliver Henry Bourne	Since November 1, 2014
Andrzej Gondek	Since May 12, 2017
Petr Podlipny	Since December 24, 2021
Filip Ludvik	Since December 24, 2021
Kazaid Adi Hazari	Since December 14, 2022 – till August 31, 2023

Each executive acts independently on the company's behalf.

1.4. Organization chart of the company as of March 31, 2024

PD 001-001_Organizační struktura_Glenmark Pharmaceuticals s.r.o.
Effective from 1st August 2019 / Platnost od 1. srpna 2019

Organizational structure / Organizační struktura
GLENMARK PHARMACEUTICALS s.r.o.



2. BASIS OF ACCOUNTING AND GENERAL ACCOUNTING PRINCIPLES

These financial statements are prepared for the year ending March 31, 2024.

The Company's accounting books and records are maintained and the financial statements were prepared in accordance with the Accounting Act 563/1991 Coll., as amended; the Regulation 500/2002 Coll. which provides implementation guidance on certain provisions of the Accounting Act for reporting entities that are businesses maintaining double-entry accounting records, as amended; and Czech Accounting Standards for Businesses, as amended.

The accounting records are maintained in compliance with general accounting principles, specifically the historical cost valuation basis, the accruals principle, the prudence concept and the going concern assumption.

These financial statements are presented in thousands of Czech crowns ('CZK').

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3.1. Tangible fixed assets

Tangible fixed assets include assets with an estimated useful life greater than one year and an acquisition cost greater than CZK 1 on an individual basis or assets from finished leasing, where the useful life is greater than one year.

Tangible fixed asset is valued at the acquisition costs which include purchase price, transportation costs and other expenses related to acquisition. Impairment of tangible assets is captured by provisions for diminution in value in the balance sheet correction column.

The cost of fixed asset improvements exceeding CZK 1 for the accounting period increases the acquisition cost of the related tangible fixed asset.

Depreciation is charged so as to write off the cost of tangible fixed assets, other than assets under construction, over their estimated useful lives, using the straight-line method, on the following basis:

	Number of years
Buildings, facilities and construction sites	50
Machines and equipment	10
Means of transportation	4
Inventory	4
Other long-term tangible property	4

3.2. Intangible fixed assets

Intangible fixed assets include assets with an estimated useful life greater than one year and an acquisition cost greater than CZK 1 on an individual basis. Intangible fixed asset is valued at the acquisition costs which include purchase price, transportation costs and other expenses related to acquisition.

Intangible fixed assets also include development activities with an estimated useful life greater than one year. Assets arising from development activities are capitalised only if utilised for repeated sale. They are valued at the lower of internal production costs and replacement cost. Intangible assets arising from research and development, software and valuable rights generated internally for the Company's internal needs are not capitalised.

Purchased intangible fixed assets are valued at cost less accumulated amortisation and any recognised impairment losses.

The cost of fixed asset improvements increases the acquisition cost of the related intangible fixed asset.

Intangibles include payments of fees related to the product registration process that are part of the cost of obtaining the product license.

Activation of long-term intangible property (licenses) occurs after the registration process is finished on behalf of the company upon the introduction of a product onto the market. The limit for activation of long-term intangible property is CZK 1.

Amortisation of licenses starts as of the activation date and lasts for 10 years in case of unlimited license rights. In situations of fixed period license agreements, the amortisation is over the period of the contract.

Amortisation of intangible fixed assets is recorded on a straight line-basis over their estimated useful lives as follows:

	Number of years
Software	5
Licenses	10

Impairment

Impairment of intangible fixed assets is recognised when the carrying value temporarily does not match the actual balance.

3.3. Financial Investment

Non-current financial assets principally consist of loans with maturity exceeding one year, equity investments, securities and equity investments available for sale and debt securities with maturity over one year held to maturity.

As defined by Section 25 paragraph letter f) of the Accounting Act, securities and shares are valued at the date (moment) of acquisition by using the acquisition prices. At the balance sheet date, they are revalued by the equivalence method.

At the balance sheet date, the Company records equity investments in subsidiaries and associates at the value established using the equity method of accounting. The equity investment recognised at cost on acquisition is revalued at the balance sheet date to reflect the value equivalent to the Company's proportion of a subsidiary's equity.

3.4. Inventory

Finished goods are valued at direct material costs, direct salaries and overhead costs. Merchandise is valued at acquisition costs. The acquisition costs mainly include purchase price, customs fees, storage costs and transportation costs if the items are transported. Work in progress is valued at direct costs. Inventory provision is created at 100% for items with expiry period less than 6 months from the balance sheet date and at 20 % for items without movement over 365 days. Provision is also created for the difference between accounting value and selling price less costs to sell (net realisable value).

3.5. Prepaid expenses

The company is posting on accounts prepaid expenses purchases of distribution rights for licenses from the company Glenmark Pharmaceuticals Europe Limited. Distribution rights are amortised over 10 years, starting when introducing product to the market.

3.6. Foreign currency translation

Transactions denominated in foreign currencies during the year are translated using the exchange rate of the Czech National Bank prevailing on the date of the transaction.

At the balance sheet date, the relevant assets and liabilities are translated at the Czech National Bank's exchange rate prevailing as of that date.

Realized and unrealized profits and losses resulting from exchange rates are calculated into revenues or costs for the regular year. In the financial statements are unrealized exchange rate losses and gains settled and recorded in the other financial expenses and Other financial revenues according to the actual balance.

3.7. Receivables

Receivables are initially recognised at their nominal value. When necessary they are reduced by appropriate provisions for doubtful and bad amounts. The provisions for receivables are created based on the aging structure of the receivables, including an individual evaluation of the borrower's credit worthiness

Impairment

Provision for accounts receivable which are overdue more than 360 days is based on the following rules:

Domestic debtors:

Receivables overdue:	Provision %:
361 – 720	5
721– 1 080	50
1 081 and more	100

Export debtors:

Receivables overdue:	Provision %:
361 – 720	10
721– 1 080	50
1 081 and more	100

3.8. Trade payables

Trade payables are recognised at their nominal value.

3.9. Provisions for liabilities and charges

Provisions are intended to cover future risks and expenditure, the nature of which is clearly defined and which are likely to be incurred, but which are uncertain as to the amount or the date on which they will arise.

3.10. Use of Estimates

The presentation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the balance sheet date and the reported amounts of revenues and expenses during the reporting period. Management of the Company has made these estimates and assumptions on the basis of all the relevant information available to it. Nevertheless, pursuant to the nature of estimates, the actual results and outcomes in the future may differ from these estimates.

3.11. Revenue Recognition

Revenue is measured at the value of the consideration received or receivable and represents amounts receivable for goods and services provided in the normal course of business, net of discounts; value added tax and other sales related taxes.

Sales of goods are recognised when goods are delivered and title has passed.

3.12. Taxes

3.12.1. Depreciation of Fixed Assets for Tax Purposes

Depreciation of fixed assets is calculated using the straight-line method for the tax purposes.

3.12.2. Current tax payable

Company has recognised a tax payable and a tax charge based on its tax calculation which follows from its understanding of the interpretation of Czech tax legislation valid at the financial statements date and believes that the amount of tax is correct in compliance with the effective Czech tax regulations. Since various interpretations of tax laws and regulations by third parties, including state administrative bodies, exist, the income tax payable reported in the Company's financial statements may change based on the ultimate opinion of the tax authorities.

3.12.3. Deferred tax

Deferred tax is accounted for using the balance sheet liability method. Deferred taxes are based on all temporary differences between the accounting and tax value of assets and liabilities using the enacted tax rate valid for the period in which these temporary differences will be settled.

The carrying amount of deferred tax assets is reviewed at the balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the asset to be recovered.

Deferred tax is charged or credited to the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the related deferred tax is also dealt with in equity.

Deferred tax assets and liabilities are offset and reported on an aggregate net basis in the balance sheet, except when partial tax assets cannot be offset against partial tax liabilities.

3.13. Cash and cash equivalents

Cash equivalents represent short-term liquid assets from which a present cash amount can be withdrawn easily and on demand.

3.14. Subsequent events

The impact of events that occurred between the balance sheet date and the date of financial statements is captured in accounting reports if these events have provided additional information about circumstances that existed at the balance sheet date.

If important events occurred between the balance sheet date and the date of financial statements due to circumstances that occurred after the balance sheet date, the consequences of those events are described in the notes to the financial statements, but are not reflected in the financial statements themselves.

4. ACCOMPANYING INFORMATIONS FOR BALANCE SHEET AND PROFIT AND LOSS STATEMENT

4.1. Intangible assets (ths CZK)

	Software	Valuable rights	Other intangibles	Total
Purchase price:				
Balance at 31.3.2023	2 490	767 260	124 456	894 206
Additions	82	60 392	149 997	210 471
Disposals	0	0	-60 474	-60 474
Balance as at 31.3.2024	2 572	827 652	213 979	1 044 203
Accumulated amortisation and impairment:				
Balance at 31.3.2023	1 830	437 435	3 958	443 223
Amortisation charge for the year	280	49 879	0	50 159
Disposals	0	0	0	0
Impairment loss	0	3 614	614	4 228
Balance as at 31.3.2024	2 110	490 928	4 572	497 610
Carrying value at 31.3.2024	462	336 724	209 407	546 593

4.2. Tangible assets (ths CZK)

	Land and Buildings	Individual movable fixed asset	Other tangibles and assets under construction	Total
Purchase price:				
Balance at 31.3.2023	210 152	162 534	11 749	384 435
Additions	1 951	27 154	23 735	52 840
Disposals	0	-4 563	-29 105	-33 668
Balance as at 31.3.2024	212 103	185 125	6 379	403 607
Accumulated depreciation:				
Balance at 31.3.2023	90 232	98 959	0	189 191
Depreciation charge for the year	4 121	13 111	0	17 232
Disposals	0	-4 539	0	-4 539
Balance as at 31.3.2024	94 353	107 531	0	201 884
Carrying value at 31.3.2024	117 750	77 594	6 379	201 723

4.3. Inventories (ths CZK)

The company has performed physical inventory count and any identified differences were accounted as surplus and shortages.

4.4. Financial investment (ths CZK)

	Company	Balance at 31.3.2024	Balance at 31.3.2023
Equity share	GLENMARK PHARMACEUTICALS SK, s. r. o.	52 968	44 521

4.5. Receivables

4.5.1. Trade receivables (ths CZK)

The standard contracted payment term is 60 days.

	Balance at 31.3.2024	Balance at 31.3.2023
Domestic trade receivables	30 085	142 032
Foreign trade receivables	1 070 182	930 843
Total (net of provision)	1 100 267	1 072 875

Aging of trade receivables

	Balance at 31.3.2024	Balance at 31.3.2023
Not yet due	483 105	653 999
Overdue	617 162	418 876
<i>thereof overdue more than 365 days</i>	<i>80 105</i>	<i>1 313</i>
Total (net of provision)	1 100 267	1 072 875

4.6. Liabilities

4.6.1. Short-term trade payables (ths CZK)

The standard credit term is 14 days.

	31.3.2024	31.3.2023
Domestic trade payables	85 155	128 799
Foreign trade payables	1 302 288	939 557
Total	1 387 443	1 068 356

Aging of trade payables

	31.3.2024	31.3.2023
Not yet due	1 086 172	1 038 331
Overdue	301 271	30 025
<i>thereof overdue more than 365 days</i>	<i>0</i>	<i>0</i>
Total	1 387 443	1 068 356

The company has not recorded any liabilities for social and health insurance which would not be settled till following month.

4.6.2. Long-term other liabilities

Long-term liability as at March 31, 2024 of CZK 30 966 ths CZK is recorded at net present value. Related interest expense is recognised in income statement over its maturity. This liability relates to out of court settlement related to one the Company's products. The company recorded long-term liability as at March 31, 2023 in the amount of 62 312 ths CZK.

4.6.3. Liabilities due to employees

The company has recorded as at March 31, 2024 liabilities due to employees in the value of 8 408 ths CZK, particularly unpaid salaries for March 2024. Liabilities due to employees as at March 31, 2023 were recorded in the value of 7 682 ths CZK.

4.6.4. Tax payables

The company has recorded as at March 31, 2024 the taxes payable in the value of 48 030 ths CZK, which represents liability from corporate income tax.

Taxes payables as at March 31, 2023 were recorded in the value of 14 007 ths CZK.

4.6.5. Accrued liabilities

The company has recorded as at March 31, 2024 accrued liabilities in the value of 86 614ths CZK primarily for not invoiced services and awaited supplier's purchase prices adjustments to the products sold (so-called price-reco) during the year ending March 31, 2024.

Accrued liabilities as at March 31, 2023 were recorded in the value of 81 874 ths CZK.

4.6.6. Short-term other liabilities

The company has recorded the short-term other liability as at March 31, 2024 in the amount of ths CZK 37 032, out of which 36 993 ths CZK represents short-term part of liability described in the point 4.6.2.

The company has recorded the short-term other liability as at March 31, 2023 in the amount of ths CZK 26 752, which represented short-term part of liability described in the point 4.6.2.

4.7. Provisions (ths CZK)

	31.3.2024	31.3.2023
Provision for unspent holiday	184 565	167 715
Provision for MSA	5 999	4 582
Provision legal services	46 601	18 668
Provision – loss compensation of Rivaroxaban	10 523	0
Provision EAAC	78	99
Total	247 766	191 064

Provision for MSA is created for contribution to cover distribution costs related to the goods sold to distribution companies in the group in the current year. Distribution companies have these goods in stock as at March 31, 2024. The provision ensures matching of expenses and revenues.

4.8. Contingent liabilities

The company has contingent liabilities from operative leasing in the amount of ths CZK 6 868 as at March 31, 2024, which are not recorded in the balance sheet; as at March 31, 2023 were liabilities from operative leasing in the amount of ths CZK 3 642.

4.9. Income from operations (ths CZK)

	2024	2023
Revenues – finished goods	527 312	376 172
Revenues – services	34 093	39 421
Revenues – merchandise	3 528 275	3 031 673
Proceeds from sale of tangible assets	13	17 321
Proceeds from sale of raw materials	2 876	3 672
Other income	341 313	353 184
Total	4 433 982	3 821 443

Revenues from sale of finished goods and services according to the geographical structure:

	2024	2023
Czech Republic	82 388	51 998
Slovak Republic	25 682	27 163
Poland	3 612	40 912
Germany	207 198	119 714
Great Britain	199 225	141 469
Sweden	4 341	13
Other	38 959	34 324
Total	561 405	415 593

4.10. Expenses

Services

Services include primarily MSA costs, which are paid to the distribution companies as a contribution for compensation of costs connected with the sale of the regulated products, which are purchased by the distribution companies in the group of Glenmark and also costs for legal services.

Other operating expenses

Other operating expenses for the year ended March 31, 2024 in the value of 345 199 ths CZK, include mainly compensation paid by the Company to other companies in Group in respect of their distribution activity for the Company. There are also insurance charges, shortages and damages, scrapping costs. For the year ended March 31, 2023 they amount to 272 044 ths CZK, and include mainly insurance charges, shortages and damages and cost of sale of distribution rights.

4.10.1. Auditor remuneration

The company has concluded the agreement for audit services with Grant Thornton Audit, s.r.o., registered by Chamber of Auditors of the Czech republic as the authorized company with license no. 603, with seat Pujmanove 1753/10a, 140 00 Praha 4. Remuneration for the auditor amounts based on the signed agreement to 615 ths CZK.

4.10.2. Current and deferred tax

The company created tax profit for the financial year ended March 31, 2024, the corporate income tax is 59 336 ths CZK, as at March 31, 2023 it was 18 254 ths CZK.

The Company booked the deferred tax in the amount 103 892 ths CZK as at March 31, 2024; as at March 31, 2023 was posted deferred tax in the amount of 70 916 ths CZK. Deferred tax as at March 31, 2024 represents following items:

Deferred tax (in ths CZK)	31.3.2024	31.3.2023
RV Tangible and intangible assets	28 358	24 062
Other provisions and adjustments	75 534	46 314
Total	103 892	70 916

5. STAFF COSTS

Average number of company employees as at March 31, 2024: 136, statutory representative wasn't employee of the Company.

Average number of company employees as at March 31, 2023: 134, statutory representative wasn't employee of the Company

	31.3.2024 (in ths CZK)	31.3.2023 (in ths CZK)
Payroll costs	102 958	87 443
Social security and health insurance costs	31 995	27 637
Social costs	6 898	6 114
Total	141 851	121 194

6. POST BALANCE SHEET EVENTS

No significant events occurred subsequent to the balance sheet date that would have a material impact on the financial statements.

Annual Report

**for the reporting period from 1 April
2023 to 31 March 2024**

Glenmark Pharmaceuticals s.r.o.

Hvězdova 1716/2b, Praha 4, 140 78

1. General information

Glenmark Pharmaceuticals s.r.o. (hereinafter the “Company”), IČ 465 05 164 was registered in the Commercial register on 6 May 1992. The registered address of the company is Hvězdova 1716/2b, Praha 4, 140 78.

Principal activities of the Company:

- Distribution of pharmaceuticals and medical equipment,
- Chemical analyses,
- manufacturing of pharmaceutical preparations,

Sole shareholder of the Company:

The sole shareholder of the Company is Glenmark Holdings SA, La Chaux-de-Fonds, Chemin de la Combeta 5, Switzerland as of March 31, 2024.

Statutory representative of the Company:

Oliver Henry Bourne (since November 1, 2014)

Andrzej Gondek (since May 12, 2017)

Petr Podlipný (since December 24, 2021)

Filip Ludvik (since December 24, 2021)

Kaizad Adi Hazari (since December 14, 2022 – till August 31, 2023)

The accounting period of the company is the fiscal year starting April 1 and ending March 31.

2. Post balance sheet events

There were no post balance sheet events having impact on financial statements as at 31.3.2024.

The Company assessed all possible impacts on its financial results of measures implemented in the Czech Republic in respect of SARS-CoV-2 (COVID 19) outbreak and the impacts of the Russian invasion of Ukraine. Considering all available information and estimates it assessed impact in all important areas including availability and procurement of goods, sales and human resources. Based on that analysis it was concluded that there is no impairment of going concern assumption based on which financial statements as of March 31, 2024 are prepared.

3. Group information


Glenmark group (hereinafter “Glenmark”) is a research-driven, global, integrated pharmaceutical company. Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with five molecules in various stages of clinical development. Glenmark has a significant presence in branded generics markets across emerging economies including India. Its subsidiary, Glenmark Generics Limited has a fast growing and robust US generics business, where the new factory was opened in 2017. The subsidiary also markets APIs to regulated and semi-regulated countries. Glenmark employs nearly 10000 people in over 80 countries. It has thirteen manufacturing facilities in four countries and has five R&D centres.

Since 2000 Glenmark is listed on the stock exchange in India and it is currently ranked among the World's top 100 Pharma & Biotech companies.

Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation, metabolic disorders and pain. Glenmark has a robust pipeline of 13 molecules in various stages of preclinical & clinical development. Of these, eight molecules are in clinical trials. Glenmark has actively followed the strategy of out-licensing its molecules in clinical development to large multinational pharmaceutical organizations. This out-licensing strategy has been successful so far. This business has three dedicated R&D centres. Discovery research for New Chemical Entities (NCEs) is carried out at its state-of-the-art research centre at Navi Mumbai, India. Glenmark’s biopharmaceutical research is carried out at its R&D facility in Switzerland. The centre is dedicated to the discovery and development of novel monoclonal antibodies (mAbs).

Glenmark’s formulations business is currently organized around four regions – India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infectives, respiratory, cardiac, diabetes, gynaecology, CNS, and oncology.

4. Group structure



5. Evaluation of the reporting period

The past year was marked by declining energy prices, which had a positive impact on the cost of producing purified water, heating the building and operation of cleanrooms in production, laboratories and warehouses. The continuing high level of inflation in the Czech Republic had a negative impact on the overall cost of production of finished products. Supply of packaging materials and primary raw materials stabilised. Introduction of alternative feedstock suppliers continued with the aim of reducing the risk of shortages on the market. The company was significantly impacted by increasing customer demand for pharmaceutical products and a new regulation requiring an increase stock in distribution, which has significantly increased demands on production capacity.

As in the previous year, internal and external audits covering GMP (Good Manufacturing Practice – audit by the State Institute for Drug Control) and ISO standards (re-certification

audit) were successfully conducted with excellent results. Development of the company's financial position and economic management is reflected in the financial statements which constitute part of the annual report.

Despite the challenging period of the entire fiscal year, the activities of the Vysoké Mýto plant achieved growth of 2% in packaged products and growth of 55% in repackaged products as compared to the previous year.

6. Anticipated development

The main problem in the coming year will be the limited production capacity and high production demands of the market. Growth of production activities is expected to be in the range of 3-5% as compared to 2023-24. Planned investments will focus mainly on increasing production capacity, workforce productivity, reducing energy dependence and automation.

Management will continue to place emphasis on employee safety, production quality and provision of customer service. Several customer audits are planned for the coming year, including an audit of ISO standards.

7. Environmental protection

The Company does not provide any activity with the significant impact on the environment. The Company complies with the local legislation with respect to the environmental area. As part of its activities, the Company makes every effort to minimise negative environmental impacts.

8. Labor relations

In the reporting period, the company was not in the insolvency and fulfilled its obligations towards Authorities, suppliers and employees properly. There no violation on the field of labor relations, the Company was not involved in any legal dispute related to the employees. In the Company isn't any Labor union founded. Further information are stated in the Notes to the financial statements.

9. Organisational branch abroad

The Company has no organisational branch abroad.

10. Research and development

The Company does not conduct any research and development activities.

Report on relationships between a controlling and a controlled entity

pursuant to Section 82 of the Corporations law

between **Glenmark Pharmaceuticals Limited, India**, as the end controlling entity, and **Glenmark Pharmaceuticals s.r.o., Czech Republic**, as the controlled entity and between Glenmark Pharmaceuticals s.r.o., Czech Republic, and other companies controlled by Glenmark Pharmaceuticals Limited, India, for the accounting period from 1 April 2023 to 31 March 2024.

In accordance with Section 82 of Act No. 90/2012 Coll., as amended, the Executive of Glenmark Pharmaceuticals s.r.o., a company with its registered seat at Hvězdova 1716/2b, Prague 4, Company ID No.: 465 05 164, registered in the Commercial Register maintained by the Municipal Court in Prague, Section C, File 150331 (hereinafter the “controlled entity”) is submitting this report on relations between Glenmark Pharmaceuticals Limited, (hereinafter the “controlling entity”), as the end controlling entity and the controlled entity and between the controlled entity and other entities controlled by Glenmark Pharmaceuticals Limited for the accounting period from 1 April 2023 to 31 March 2024.

Other entities, controlled by Glenmark Pharmaceuticals Limited, India, for the accounting period are understood particularly as these companies:

- Glenmark Pharmaceuticals SK, s.r.o., Slovakia
- Glenmark Pharmaceuticals, Sp.z.o.o, Poland
- Glenmark Pharmaceuticals Ltd., India
- Glenmark Pharmaceuticals Europe Limited, UK
- Glenmark Specialty S.A., Switzerland
- Glenmark Pharmaceuticals Distribution, Czech Republic
- VISO Farmaceutica S.L.U., Spain
- Glenmark Pharmaceuticals Nordic AB, Sweden
- Glenmark Arzneimittel GmbH, Germany
- Glenmark Pharmaceuticals B.V., Netherlands
- and other companies within the Glenmark group.

As of 31 March 2024, Glenmark Pharmaceuticals s.r.o., Czech Republic, was controlled 100% by Glenmark Holding SA, Switzerland.

As of 31 March 2024, Glenmark Holding SA, Switzerland, was controlled 100% by Glenmark Pharmaceuticals Limited, India.

As of 31 March 2024, Glenmark Pharmaceuticals SK, s.r.o., Slovakia, was controlled 100% by Glenmark Pharmaceuticals s.r.o., Czech Republic.

As of 31 March 2024, all of the companies named above were controlled 100 % by Glenmark Pharmaceuticals Limited, India, as the end controlling entity and comprise a concern together with them.

The companies have not entered into a controlling agreement.

Between the connected entities in the sense of Section 82 of Act No. 90/2012 Coll., as amended, the following agreements were entered into, the following measures were taken and the following legal acts were performed:

Agreements:

Glenmark Pharmaceuticals Limited, India

- Distribution agreement – agreement governs the purchase of goods from Glenmark Pharmaceuticals Limited
- Marketing Expenses Recharging Agreement – agreement governs compensation of marketing expenses for in-house products

Glenmark Pharmaceuticals, Sp.z o.o, Poland

- Agreement on marketing cooperation – agreement on supporting of marketing activities of Glenmark Pharmaceuticals, Sp. z o.o.
- Distribution Agreement – agreement governs sale of products and goods to the company Glenmark Pharmaceuticals, Sp.z o.o.
- Marketing Expenses Recharging Agreement – agreement on compensation of marketing costs related to in-house products
- Marketing Expenses Recharging Agreement – agreement governs compensation of marketing costs related to product Ryaltris
- Agreement on Remuneration for Services – agreement on providing of repacking services of products by the company Glenmark Pharmaceuticals s.r.o.

Glenmark Pharmaceuticals SK, s.r.o., Slovakia

- Agreement on marketing cooperation - agreement on supporting of marketing activities of the company Glenmark Pharmaceuticals SK, s.r.o.
- Distribution agreement – agreement governs the sale of products and goods to Glenmark Pharmaceuticals SK, s.r.o.
- Agreement on Provision of Services – agreement governs purchasing of logistics and supply chain services related to in-licensed products
- Agreement on Remuneration for Services- agreement governs providing of repacking services of products by the company Glenmark Pharmaceuticals s.r.o.

Glenmark Pharmaceuticals Distribution s. r. o.

- Agreement on marketing cooperation - agreement on supporting of marketing activities of the company Glenmark Pharmaceuticals Distribution, s.r.o.
- Distribution agreement - agreement governs the sale of products and goods to Glenmark Pharmaceuticals Distribution s.r.o.
- Service Agreement – agreement about accounting and administrative services provided to the company Glenmark Pharmaceuticals s.r.o.

Glenmark Specialty S.A., Switzerland

- Marketing Expenses Recharging Agreement – compensation of marketing costs related to product Ryaltris

Glenmark Specialty S.A., Switzerland; Glenmark Pharmaceuticals Limited, India

- Supply and Distribution Agreement – agreement governs delivery and purchase/sale of in-house products

Glenmark Specialty S.A., Switzerland; Glenmark Pharmaceuticals Limited, India; Glenmark Pharmaceuticals Europe Limited, UK

- Supply and Distribution Agreement – agreement governs delivery and purchase/sale of in-house products

Glenmark Pharmaceuticals Europe Limited, UK

- Technical Agreement – agreement governs re-invoicing of costs connected with testing and repacking products to the company Glenmark Pharmaceuticals Europe Limited
- Service Agreement – agreement on purchasing of the services in the area of invoicing, demand planning, regulatory services, finance, accounting and third party sales management within portfolio of in-house products
- Distribution agreement - agreement governs the sale of products and goods to the company Glenmark Pharmaceuticals Europe Limited

Viso Farmaceutica S. L. U., Spain

- Compensation Agreement – agreement governs compensation of costs of the company Viso Farmaceutica S. L. U. in order to achieve profitability according to benchmarking profitability study of pharmaceutical distributors in EU
- Distribution Agreement – agreement governs the sale of products and goods
- Agreement on Remuneration for Services - agreement governs providing of repacking services of products by the company Glenmark Pharmaceuticals s.r.o.

Glenmark Pharmaceuticals Nordic AB, Sweden

- Agreement - agreement governs compensation of costs of the company Glenmark Pharmaceuticals Nordic AB in order to achieve profitability as at 31.3.2024 according to benchmarking profitability study of pharmaceutical distributors in EU
- Agreement – agreement governs re-invoicing of costs related to purchasing of substitutes in the tender
- Distribution Agreement – agreement governs the sale of products and goods
- Agreement on Remuneration for Services- agreement governs providing of repacking services of products by the company Glenmark Pharmaceuticals s.r.o.

Glenmark Arzneimittel GmbH, Germany

- Distribution Agreement – agreement governs the sale of products and goods
- Agreement on Remuneration for Services- agreement governs providing of repacking services of products by the company Glenmark Pharmaceuticals s.r.o.

Glenmark Pharmaceuticals B.V., Netherlands

- Distribution Agreement – agreement governs the sale of products and goods
- Agreement on Remuneration for Services- agreement governs providing of repacking services of products by the company Glenmark Pharmaceuticals s.r.o.
- Agreement on Provision of Services – agreement governs purchasing of services in the area of business development in-licensed products

Sintesy Pharma S.r.l., Italy

- Compensation Agreement – agreement governs compensation of costs of the company Sintesy Pharma S.r.l. in order to achieve profitability according to benchmarking profitability study of pharmaceutical distributors in EU

Overview of transactions of the controlling entity or from contractual relationships between the controlled entities which have more than 10% share on equity in controlling entity according to the last known financial statements:

Costs and revenues

	As of 31.3.2024	As of 31.3.2023
	ths CZK	ths CZK
Costs:		
Purchase of goods	1 335 414	1 068 377
Marketing services	723 921	736 488
Other operating expense	16 385	44 445
Total	2 075 720	1 849 310
Revenues:		
Sale of products	489 732	318 352
Sale of goods	2 900 845	2 695 040
Services	28 317	27 914
Other operational revenues	76 639	150 776
Interest received	62	0
Total	3 495 595	3 192 082

Balance of receivables and obligations of the controlled entity from contractual relationships between the controlled entity and connected entities:

Trade receivables

	As of 31.3.2024	As of 31.3.2023
	ths CZK	ths CZK
Glenmark Pharmaceuticals SK, s.r.o.	159 094	127 267
Glenmark Pharmaceuticals, Sp.z.o.o	151 634	130 434
Glenmark Pharmaceuticals Europe	164 483	241 514
Glenmark Arzneimittel GmbH	19 026	24 172
Glenmark Pharmaceutical LTD	180 598	139 774
Viso Pharmaceutica S.L.U.	33 451	30 147
Glenmark Pharma Nordic (SE)	185 185	119 692
Glenmark Pharmaceuticals B.V.	37 001	16 032
Glenmark Specialty S. A.	1 008	1 209
Glenmark Pharm. Distribution	29 983	141 827
Glenmark Generics S. A.	629	584
Sintesy Pharma S.r.l.	2 311	0
Total	964 403	127 267

Trade payables

	As of 31.3.2024	As of 31.3.2023
	ths CZK	ths CZK
Glenmark Pharmaceuticals Sp, z.o.o.	53 843	39 818
Glenmark Specialty S. A.	17 964	97 092
Glenmark Pharmaceuticals Ltd.	845 882	491 043
Glenmark Pharmaceuticals Europe	11 870	18 161
Glenmark Arzneimittel GmbH	24 886	21 301
Glenmark Pharmaceuticals B.V.	2 233	819
Glenmark Pharmaceuticals Nordic AB	5 054	0
Glenmark Pharm. Distribution	70 882	114 244
Glenmark Pharmaceuticals SK, s.r.o.	15 402	35 296
Sintesy Pharma S.r.l.	5 129	0
Total	1 053 145	817 774

Balances related to the financial investment:

Financial Investment

	As of 31.3.2024	As of 31.3.2023
	ths CZK	ths CZK
Glenmark Pharmaceuticals SK, s.r.o.	52 968	44 521

Revaluation of financial investments was done through equivalence.

Glenmark Pharmaceuticals s.r.o. did not suffer any harm from its relationships with connected entities during the finished period.